{"product_id":"international-asthma-conference-at-nemacolin-20th-annual-meeting-2025","title":"International Asthma Conference at Nemacolin 20th Annual Meeting 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: pulmonologists, allergists, and immunologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e1. Overview\u003c\/p\u003e\n\u003cp\u003eThe International Asthma Conference at Nemacolin 20th Annual Meeting provides a comprehensive update on the latest clinical and scientific advancements in asthma management. The program covers a broad spectrum of topics, including early-life determinants of asthma, the integration of biomarkers and molecular phenotyping, the safety and efficacy of biologic therapies, and strategies for achieving disease remission in both pediatric and adult populations.\u003c\/p\u003e\n\u003cp\u003e2. Learning Objectives\u003c\/p\u003e\n\u003cp\u003eEvaluate the role of early-life viral infections, epigenetics, and social determinants in the etiology and long-term trajectory of childhood asthma.\u003c\/p\u003e\n\u003cp\u003eApply advanced clinical and molecular phenotyping and endotyping to personalize asthma treatment and advance towards disease remission.\u003c\/p\u003e\n\u003cp\u003eAssess the safety considerations, clinical applications, and controversies surrounding the use of biologic therapies and rescue medications in asthma and COPD exacerbations.\u003c\/p\u003e\n\u003cp\u003eNavigate current legal and policy barriers related to the integration of AI in respiratory medicine.\u003c\/p\u003e\n\u003cp\u003eUnderstand the evolving safety profiles of inhaled corticosteroids and long-acting beta-agonists, and reevaluate the role of oral corticosteroids in the modern biologics era.\u003c\/p\u003e\n\u003cp\u003e3. Target Audience\u003c\/p\u003e\n\u003cp\u003eBest for pulmonologists, allergists, and immunologists who want updates on asthma endotyping, biologic therapies, and disease prevention strategies.\u003c\/p\u003e\n\u003cp\u003e4. Topics\u003c\/p\u003e\n\u003cp\u003e01 AI in Medicine – Navigating Current Legal and Policy Barriers\u003c\/p\u003e\n\u003cp\u003e03 Asthma Remission—Current Evidence and Clinical Implications\u003c\/p\u003e\n\u003cp\u003e04 Asthma Remission – Strategies and Barriers in Achieving Disease Control\u003c\/p\u003e\n\u003cp\u003e05 Roundtable Discussion Q\u0026amp;A – The Beginning and Ending of Asthma\u003c\/p\u003e\n\u003cp\u003e06 Update on Gene Therapy for Lung Disease\u003c\/p\u003e\n\u003cp\u003e07 Role of Empathy in Improving Patient–Provider Relationships\u003c\/p\u003e\n\u003cp\u003e08 Safety Considerations for Biologic Therapies – What Should Clinicians Watch For\u003c\/p\u003e\n\u003cp\u003e09 Asthma Trajectories From Childhood to Adulthood – Dunedin Cohort Findings\u003c\/p\u003e\n\u003cp\u003e10 Asthma and Allergy in Childhood – Key Findings from the Manchester Asthma and Allergy Study\u003c\/p\u003e\n\u003cp\u003e11 CHILD Cohort – Longitudinal Discovery in Asthma Prevention Strategies\u003c\/p\u003e\n\u003cp\u003e12 Childhood Asthma Etiology – ECHO Cohort and CADRE Collaboration Insights\u003c\/p\u003e\n\u003cp\u003e13 Viruses, Asthma, and Maternal Vaccines – Changing the Trajectory of Childhood Disease\u003c\/p\u003e\n\u003cp\u003e14 Asthma Exacerbation in Children – Mechanisms of Rhinovirus-Triggered Events\u003c\/p\u003e\n\u003cp\u003e15 Roundtable Discussion Q\u0026amp;A – Viruses and Asthma\u003c\/p\u003e\n\u003cp\u003e16 A Biologic Should Be Administered as a Rescue Medication for Acute Eosinophilic Asthma and COPD Exacerbations – PRO\u003c\/p\u003e\n\u003cp\u003e17 A Biologic Should Be Administered as a Rescue Medication for Acute Eosinophilic Asthma and COPD Exacerbations – CON\u003c\/p\u003e\n\u003cp\u003e18 Roundtable Discussion Q\u0026amp;A – Biologics and Asthma\u003c\/p\u003e\n\u003cp\u003e19 Treatable Traits in Asthma – Clinical Approach to Laryngeal Involvement\u003c\/p\u003e\n\u003cp\u003e20 Asthma Phenotyping – Clinical Characteristics to Molecular Approaches\u003c\/p\u003e\n\u003cp\u003e21 Asthma in Children – Advances in Clinical and Molecular Phenotyping\u003c\/p\u003e\n\u003cp\u003e22 Asthma Biomarkers – Applications and Limitations in Clinical Management\u003c\/p\u003e\n\u003cp\u003e23 Asthma Endotyping – Advancing Remission and Curative Strategies\u003c\/p\u003e\n\u003cp\u003e24 Roundtable Discussion Q\u0026amp;A – Asthma Heterogeneity and the Evolution of Phenotyping\u003c\/p\u003e\n\u003cp\u003e25 Origins of Asthma—Key Mechanisms in Disease Development and Progression\u003c\/p\u003e\n\u003cp\u003e26 Asthma and Epigenetics – Environmental Factors Influencing Disease Pathogenesis\u003c\/p\u003e\n\u003cp\u003e27 Asthma Exacerbations – Navigating the Role of Air Pollution in Disease Management\u003c\/p\u003e\n\u003cp\u003e28 Asthma Outcomes and Social Determinants—What Clinicians Need to Know\u003c\/p\u003e\n\u003cp\u003e29 Roundtable Discussion Q\u0026amp;A – Determinants of Asthma\u003c\/p\u003e\n\u003cp\u003e30 Managing Pediatric Asthma – What Are the Safety Risks of Inhaled Corticosteroids\u003c\/p\u003e\n\u003cp\u003e31 Orbital Manifestations of Cushing’s Syndrome – Diagnostic and Management Strategies\u003c\/p\u003e\n\u003cp\u003e32 Asthma in the Biologics Era – Should Oral Corticosteroid Therapy be Relegated to History\u003c\/p\u003e\n\u003cp\u003e33 Long-Acting Beta-Agonists – How Has Safety Understanding Changed Over Time\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405820481732,"sku":null,"price":35.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/medicalcoursespro.com\/products\/international-asthma-conference-at-nemacolin-20th-annual-meeting-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}